Literature DB >> 19161998

Presence of high-molecular-weight forms and domain alterations of fibronectin in pleural effusion of patients with lung cancer.

Małgorzata Pupek1, Dorota Krzyzanowska-Gołab, Tomasz Dyła, Anna Lemańska-Perek, Renata Jankowska, Iwona Katnik-Prastowska.   

Abstract

OBJECTIVES: Appearance of fibronectin (FN) molecular forms and alterations of domain expositions can be associated with lung cancer. DESIGN AND METHODS: The presence of the FN molecular forms and epitopes in its cell-binding, carboxyl-, and amino-terminal domains was determined in the plasma and pleural effusion of patients suffering from small- and non-small-cell lung cancer, and lung inflammation by immunoblotting and FN-ELISA.
RESULTS: The 320-kDa and 280-kDa FN forms as well as FN fragments appeared in the pleural effusion and plasma of patients suffering from lung inflammation or cancer in significantly higher relative amounts in both lung cancer groups than in the inflammation. The domain concentrations were higher in the cancer and inflammatory plasma groups than those in the control group. The higher N-terminal epitope expression in pleural effusion than in plasma indicates different epitope accessibility for the monoclonal antibody.
CONCLUSIONS: The molecular status of FN probably reflects the dynamic changes which occur in cancer and inflammatory tissue.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161998     DOI: 10.1016/j.clinbiochem.2008.12.018

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Time-dependent changes in extra-domain A-fibronectin concentration and relative amounts of fibronectin-fibrin complexes in plasma of patients with peripheral arterial disease after endovascular revascularisation.

Authors:  Małgorzata Pupek; Dorota Krzyżanowska-Gołąb; Daniel Kotschy; Wojciech Witkiewicz; Wiesława Kwiatkowska; Maria Kotschy; Iwona Kątnik-Prastowska
Journal:  Int Wound J       Date:  2018-03-13       Impact factor: 3.315

2.  Analysis of Soluble Molecular Fibronectin-Fibrin Complexes and EDA-Fibronectin Concentration in Plasma of Patients with Atherosclerosis.

Authors:  Anna Lemańska-Perek; Dorota Krzyżanowska-Gołąb; Małgorzata Pupek; Piotr Klimeczek; Wojciech Witkiewicz; Iwona Kątnik-Prastowska
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis.

Authors:  Anna Lemańska-Perek; Dorota Krzyżanowska-Gołąb; Tomasz Skalec; Barbara Adamik
Journal:  Mediators Inflamm       Date:  2020-08-01       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.